Weekly Investment Analysts’ Ratings Changes for Liquidia (LQDA)

Several analysts have recently updated their ratings and price targets for Liquidia (NASDAQ: LQDA):

• 7/24/2026 – Liquidia was given a new $130.00 price target by Royal Bank Of Canada.
• 7/24/2026 – Liquidia was given a new $36.00 price target by HC Wainwright.
• 7/24/2026 – Liquidia was given a new $129.00 price target by Piper Sandler.
• 7/24/2026 – Liquidia was given a new $130.00 price target by Stephens.
• 7/23/2026 – Liquidia had its price target raised by HC Wainwright from $75.00 to $130.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Liquidia had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/29/2026 – Liquidia had its “neutral” rating reaffirmed by Bank of America Corporation. They now have a $79.00 price target on the stock, up from $64.00.
• 6/27/2026 – Liquidia was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/22/2026 – Liquidia had its price target raised by BTIG Research from $59.00 to $109.00. They now have a “buy” rating on the stock.
• 6/5/2026 – Liquidia had its price target raised by HC Wainwright from $67.00 to $75.00. They now have a “buy” rating on the stock.
• 6/5/2026 – Liquidia was given a new $75.00 price target by Oppenheimer Holdings, Inc..
• 6/5/2026 – Liquidia was given a new $28.00 price target by HC Wainwright.
• 6/4/2026 – Liquidia had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $68.00 price target on the stock.

Insider Buying and Selling at Liquidia

In other Liquidia news, insider Jason Adair sold 688 shares of Liquidia stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $87.53, for a total value of $60,220.64. Following the completion of the sale, the insider directly owned 216,438 shares in the company, valued at $18,944,818.14. The trade was a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sanjeev Khindri sold 1,185 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total transaction of $84,739.35. Following the completion of the sale, the insider directly owned 65,947 shares of the company’s stock, valued at $4,715,869.97. This represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 2,200,754 shares of company stock worth $144,924,608 over the last quarter. Insiders own 25.60% of the company’s stock.

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).